The D.I.S.C.O. hosts discuss the agency’s first approval of a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.<br>
Transcript

The D.I.S.C.O. hosts discuss the agency’s first approval of a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. Transcript

FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval Transcript

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.

Share FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval Transcript

Sign up to save your podcasts

FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval Transcript

FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval Transcript